Celgene Corp - Company Profile
Powered by
All the data and insights you need on Celgene Corp in one report.
- Save hours of research time and resources with
our up-to-date Celgene Corp Strategy Report
- Understand Celgene Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Celgene Corp (Celgene), a subsidiary of Bristol-Myers Squibb Co, is an integrated biopharmaceutical company that discovers, develops, manufactures, and markets novel gene and protein regulation therapies for the treatment of cancer and immune-inflammatory diseases. Its major product portfolio includes Revlimid (lenalidomide), Pomalyst (pomalidomide) and Thalomid (thalidomide) for the treatment of multiple myeloma; and Abraxane (paclitaxel albumin-bound particles for injectable suspension) for various types of cancers, among others. The company sells its products through own sales organizations and distributors in Europe, the Middle-East, the Americas, and Asia-Pacific. Celgene is headquartered in Summit, New Jersey, the US.
Celgene Corp premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Marketed | Vidaza |
Paclitaxel Protein-Bound Particles For Injectable Suspension (Albumin-Bound) | Abraxane |
Thalidomide | Istodax |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
Competitor Comparison
Key Parameters | Celgene Corp | Johnson & Johnson | Merck & Co Inc | Sanofi | Novartis AG |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United States of America | France | Switzerland |
City | Summit | New Brunswick | Kenilworth | Paris | Basel |
State/Province | New Jersey | New Jersey | New Jersey | Ile-de-France | - |
No. of Employees | - | 131,900 | 72,000 | 87,994 | 76,057 |
Entity Type | Private | Public | Public | Public | Public |
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer